Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00416403 · ClinicalTrials.gov registry record · Phase 2

Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer

A Phase 2 study, sponsored by University of California, San Francisco.

Completed
Registry status
Phase 2
Development phase
35
Enrollment target

NCT00416403 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 35 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00416403, a Phase 2 study, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target

Study Summary

RATIONALE: Collecting samples of blood and tissue from patients with cancer to study in the laboratory may help doctors learn how fluvastatin effects biomarkers related to breast cancer. PURPOSE: This randomized phase II trial is studying how fluvastatin effects biomarkers in women undergoing surgery for ductal carcinoma in situ or stage I breast cancer.

Interventions

  • DRUG fluvastatin sodium
  • PROCEDURE Breast Cancer Surgery Only - Arm III

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2006-07
Est. Completion 2011-06
Phase Phase 2

What the Registry Record Tells You About NCT00416403

The ClinicalTrials.gov registry entry for NCT00416403 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which fluvastatin sodium is the first listed.

NCT00416403 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00416403 about?

NCT00416403 is a clinical study titled "Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer". RATIONALE: Collecting samples of blood and tissue from patients with cancer to study in the laboratory may help doctors learn how fluvastatin effects biomarkers related to breast cancer. PURPOSE: This randomized phase II trial is studying how fluvastatin effects biomarkers in women undergoing surge...

What is the current status of trial NCT00416403?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2006-07. Estimated completion is 2011-06.

What interventions are being tested in trial NCT00416403?

The interventions under investigation include: fluvastatin sodium (DRUG), Breast Cancer Surgery Only - Arm III (PROCEDURE).

Who is sponsoring clinical trial NCT00416403?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.